{"id":"gemigliptin-ls15-0444","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Hypoglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting DPP-4, gemigliptin prevents the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), allowing these hormones to accumulate and enhance glucose-dependent insulin secretion. This mechanism reduces blood glucose levels in patients with type 2 diabetes while minimizing hypoglycemia risk since insulin secretion is glucose-dependent.","oneSentence":"Gemigliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases levels of incretin hormones to stimulate insulin secretion in response to glucose.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:56.122Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT02343926","phase":"PHASE3","title":"Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-12","conditions":"Type 2 Diabetes Mellitus","enrollment":443}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zemiglo"],"phase":"phase_3","status":"active","brandName":"GEMIGLIPTIN LS15-0444","genericName":"GEMIGLIPTIN LS15-0444","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gemigliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases levels of incretin hormones to stimulate insulin secretion in response to glucose. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}